Kana Shimizu

Koji Hasegawa

Masafumi Funamoto

Satoshi Shimizu

Tatuya Morimoto

Yasufumi Katanasaka

Yoichi Sunagawa

Yusuke Miyazaki

Yuto Kawase

European Cardiology Review

PubMed

Directory of Open Access Journals

ISCP Posters© RADCLIFFE CARDIOLOGY 2021Access at: www.ECRjournal.comObjectives: Cardiac remodelling is a compensatory mechanism associated with cardiomyocyte hypertrophy and cardiac fibrosis. This process eventually results in chronic heart failure. In this study, we screened a natural compound library for compounds that suppress both hypertrophic and fibrotic responses, and found compound A, a ginger extract. The purpose of this study is to investigate the effect of compound A on cardiomyocyte hypertrophy, cardiac fibrosis and the development of heart failure.Materials and methods: First, primary cultured cardiomyocytes and cardiac fibroblasts were treated with 1 µM compound A, then stimulated with phenylephrine or transforming growth factor-β (TGF-β), respectively. Immunofluorestaining and qPCR were performed on cardiomyocytes. Measurement of L-proline incorporation, qPCR and western blotting were carried out on cardiac fibroblasts. C57BL/6J mice were subjected to transverse aortic constriction (TAC) surgery, then given a daily oral administration of 1 mg/kg compound A for 8 weeks. Echocardiographic analysis and measurement of heart weight to body weight (HW/BW) ratio were performed.Results: In cultured cardiomyocytes, 1 µM of compound A suppressed phenylephrine-induced increases in the surface area of cardiomyocytes and in the mRNA levels of ANF and BNP. In cultured cardiac fibroblasts, the compound also suppressed TGF-β-induced L-proline incorporation, and mRNA and protein levels of α-smooth muscle actin. In heart failure model mice, echocardiographic analysis showed that 1 mg/kg of compound A prevented a TAC-induced increase in posterior wall thickness and a decrease in systolic dysfunction. The compound also suppressed a TAC-induced increases in HW/BW ratio.Conclusion: Compound A may be an effective agent for heart failure therapy. Citation: European Cardiology Review 2021;16:e57. DOI: https://doi.org/10.15420/ecr.2021.16.PO1Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.Young Investigator Award Compound A, a Ginger Extract, Significantly Reduces Pressure Overload-induced Systolic Heart Failure in MiceYuto Kawase,1 Kana Shimizu,1,2 Masafumi Funamoto,1,2 Yoichi Sunagawa,1,2,3 Yasufumi Katanasaka,1,2,3 Yusuke Miyazaki,1,2,3 Satoshi Shimizu,1,2 Koji Hasegawa1,2 and Tatuya Morimoto1,2,31. University of Shizuoka, Shizuoka, Japan; 2. Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan; 3. Shizuoka General Hospital, Shizuoka, Japan

Compound A, a Ginger Extract, Significantly Reduces Pressure Overload-induced Systolic Heart Failure in Mice

https://assets.radcliffecardiology.com/s3fs-public/article-pdf/2021-12/ECR_ISCP_posters_2021_WEB_e57.pdf?VersionId=yR9EKB8yB4SW.NjTu6hnHAtyq38UMOot

Compound A, a Ginger Extract, Significantly Reduces Pressure Overload-induced Systolic Heart Failure in Mice

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals